JNJ

Johnson & Johnson remains a high-quality healthcare compounder with durable positions across Innovative Medicine and MedTech, benefiting from scale, global distribution, and deep R&D. Near-term investor focus is shifting to how well J&J replaces Stelara’s erosion with newer immunology, oncology and neuroscience assets, while sustaining steady MedTech procedure recovery. The company’s ability to raise 2026 sales guidance despite a major product headwind supports the view that the portfolio is still structurally resilient.

Financially, momentum is solid: Q1 2026 sales grew 9.9% to $24.1B with EPS of $2.14 and adjusted EPS of $2.70. Management raised 2026 guidance to about $100.8B revenue at the midpoint and maintained/anchored adjusted EPS around $11.53–$11.55, implying continued earnings growth. Valuation looks reasonable for quality at roughly ~22x trailing earnings and ~18–21x forward estimates, alongside a $5.20 annual dividend (~2% yield), though coverage is limited on current balance-sheet and cash-flow details.

Thesis: JNJ offers a relatively defensive way to own healthcare innovation with improving operational execution, but the stock’s upside hinges on post-Stelara growth durability and litigation overhang management. Key 12-month catalysts include continued guidance raises, clearer evidence of pipeline/commercial offset to Stelara, and stabilization in headline legal risk. Key risks are faster-than-expected immunology decline, deal execution risk, and valuation compression if rates rise or growth disappoints.

Recommendation: HOLD. Guidance strength and business durability support downside protection, but the current valuation already prices in much of the “quality premium” while product-transition and legal headlines can cap near-term upside.